Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Status:
Withdrawn
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the rate of response to the drugs bortezomib
(Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed
(recurrent) and/or refractory (difficult to treat) non-Hodgkin Lymphoma, and to determine the
safety and tolerability of this regimen.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System